Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PEDRO M BARATA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1841746542
CMS profile
5698885
Location
NEW ORLEANS, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$83,836.36

105 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PEDRO M BARATA

NPI 1841746542 · CMS profile ID 5698885

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NEW ORLEANS, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841746542?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PEDRO M BARATA, NPI 1841746542, CMS profile ID 5698885. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841746542?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). PEDRO M BARATA, NPI 1841746542, CMS profile ID 5698885. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841746542?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
PEDRO M BARATA, NPI 1841746542, CMS profile ID 5698885, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1841746542?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

105 matching records · $83,836.36 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 105 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–105 of 105.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Myovant Sciences Inc. $53.1402/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941178767 CMS
Clovis Oncology, Inc. $142.4602/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924876425 CMS
PFIZER INC. $3,780.0001/21/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949510121 CMS
Exelixis Inc. $89.9701/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932459929 CMS
Seagen Inc. $1,826.0001/14/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904123525 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $38,767.68 83
PY2020 $45,578.78 51
PY2021 $39,777.89 27
PY2022 $83,836.36 105
PY2023 $193,376.73 134
PY2024 $194,477.35 162
PY2025 $331,930.79 161

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $4,800.00 4
PY2025 Principal investigator $1,048,759.23 132
PY2024 Recipient $940.00 1
PY2024 Principal investigator $1,572,363.97 142
PY2023 Recipient $7,660.00 11
PY2023 Principal investigator $300,949.93 71
PY2022 Recipient $6,400.00 2
PY2022 Principal investigator $149,126.84 32
PY2021 Principal investigator $116,554.59 17
PY2020 Principal investigator $75,972.52 14
PY2019 Principal investigator $58,130.56 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

136 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $205,985.55 12/31/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
MK-5684-003# A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer mCRPC Previously Treated With Next-generation Hormonal Agent NHA No dispute reported 06/30/2026 1232929873
Principal investigator 1 Merck Sharp & Dohme LLC $41,259.56 12/31/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Treatment with One Next generation Hor No dispute reported 06/30/2026 1232930215
Principal investigator 1 Janssen Research & Development, LLC $35,248.00 12/29/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer No dispute reported 06/30/2026 1175354153
Principal investigator 1 Janssen Research & Development, LLC $38,466.00 12/29/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer No dispute reported 06/30/2026 1175354531
Principal investigator 1 Exelixis Inc. $4,853.70 12/26/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377670
Recipient PFIZER INC. $3,200.00 12/22/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727015
Principal investigator 1 Janssen Research & Development, LLC $56,571.00 12/15/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175354217
Principal investigator 1 Exelixis Inc. $4,243.00 12/10/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377678
Principal investigator 1 Exelixis Inc. $31,700.40 12/01/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377668
Principal investigator 1 Janssen Research & Development, LLC $2,227.00 11/28/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer No dispute reported 06/30/2026 1175354161
Principal investigator 1 Exelixis Inc. $2,230.00 11/19/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377672
Principal investigator 1 Exelixis Inc. $2,416.00 11/19/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377674
Principal investigator 1 Exelixis Inc. $2,836.00 11/19/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377676
Principal investigator 1 Exelixis Inc. $2,314.00 11/19/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377680
Principal investigator 1 Janssen Research & Development, LLC $25,545.00 11/10/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer No dispute reported 06/30/2026 1175354508
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,000.00 11/07/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913695
Principal investigator 1 Aveo Pharmaceuticals, Inc. $500.00 11/07/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913697
Principal investigator 1 Aveo Pharmaceuticals, Inc. $200.00 11/07/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913699
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,000.00 11/07/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913713
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,000.00 11/07/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913715
Principal investigator 1 Aveo Pharmaceuticals, Inc. $500.00 11/07/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913755
Principal investigator 1 Janssen Research & Development, LLC $46,475.00 11/03/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer No dispute reported 06/30/2026 1175354333
Recipient PFIZER INC. $330.00 10/20/2025 Covered Recipient Physician MEVROMETOSTAT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727577
Principal investigator 1 Aveo Pharmaceuticals, Inc. $273.70 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913667
Principal investigator 1 Aveo Pharmaceuticals, Inc. $322.28 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913669
Principal investigator 1 Aveo Pharmaceuticals, Inc. $273.70 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913671
Principal investigator 1 Aveo Pharmaceuticals, Inc. $273.70 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913673
Principal investigator 1 Aveo Pharmaceuticals, Inc. $275.52 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913675
Principal investigator 1 Aveo Pharmaceuticals, Inc. $188.02 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913677
Principal investigator 1 Aveo Pharmaceuticals, Inc. $304.92 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913679
Principal investigator 1 Aveo Pharmaceuticals, Inc. $304.92 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913681
Principal investigator 1 Aveo Pharmaceuticals, Inc. $304.92 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913683
Principal investigator 1 Aveo Pharmaceuticals, Inc. $304.92 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913685
Principal investigator 1 Aveo Pharmaceuticals, Inc. $188.02 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913687
Principal investigator 1 Aveo Pharmaceuticals, Inc. $430.92 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913689
Principal investigator 1 Aveo Pharmaceuticals, Inc. $273.70 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913691
Principal investigator 1 Aveo Pharmaceuticals, Inc. $304.92 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913693
Principal investigator 1 Aveo Pharmaceuticals, Inc. $299.32 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913701
Principal investigator 1 Aveo Pharmaceuticals, Inc. $275.52 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913703
Principal investigator 1 Aveo Pharmaceuticals, Inc. $304.92 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913705
Principal investigator 1 Aveo Pharmaceuticals, Inc. $304.92 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913707
Principal investigator 1 Aveo Pharmaceuticals, Inc. $299.32 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913709
Principal investigator 1 Aveo Pharmaceuticals, Inc. $273.70 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913711
Principal investigator 1 Aveo Pharmaceuticals, Inc. $273.70 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913717
Principal investigator 1 Aveo Pharmaceuticals, Inc. $13.89 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913719
Principal investigator 1 Aveo Pharmaceuticals, Inc. $275.52 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913721
Principal investigator 1 Aveo Pharmaceuticals, Inc. $13.89 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913723
Principal investigator 1 Aveo Pharmaceuticals, Inc. $304.92 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913725
Principal investigator 1 Aveo Pharmaceuticals, Inc. $430.92 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913727
Principal investigator 1 Aveo Pharmaceuticals, Inc. $430.92 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913729
Principal investigator 1 Aveo Pharmaceuticals, Inc. $13.89 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913731
Principal investigator 1 Aveo Pharmaceuticals, Inc. $188.02 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913733
Principal investigator 1 Aveo Pharmaceuticals, Inc. $13.89 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913735
Principal investigator 1 Aveo Pharmaceuticals, Inc. $273.70 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913737
Principal investigator 1 Aveo Pharmaceuticals, Inc. $273.70 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913739
Principal investigator 1 Aveo Pharmaceuticals, Inc. $273.70 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913741
Principal investigator 1 Aveo Pharmaceuticals, Inc. $283.78 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913743
Principal investigator 1 Aveo Pharmaceuticals, Inc. $13.89 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913745
Principal investigator 1 Aveo Pharmaceuticals, Inc. $283.78 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913747
Principal investigator 1 Aveo Pharmaceuticals, Inc. $13.89 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913749
Principal investigator 1 Aveo Pharmaceuticals, Inc. $273.70 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913751
Principal investigator 1 Aveo Pharmaceuticals, Inc. $275.52 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913753
Principal investigator 1 Aveo Pharmaceuticals, Inc. $322.28 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913757
Principal investigator 1 Aveo Pharmaceuticals, Inc. $322.28 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913759
Principal investigator 1 Aveo Pharmaceuticals, Inc. $322.28 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913761
Principal investigator 1 Aveo Pharmaceuticals, Inc. $273.70 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913763
Principal investigator 1 Aveo Pharmaceuticals, Inc. $304.92 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913765
Principal investigator 1 Aveo Pharmaceuticals, Inc. $13.89 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913767
Principal investigator 1 Aveo Pharmaceuticals, Inc. $304.92 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913769
Principal investigator 1 Aveo Pharmaceuticals, Inc. $304.92 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913771
Principal investigator 1 Aveo Pharmaceuticals, Inc. $13.89 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913773
Principal investigator 1 Aveo Pharmaceuticals, Inc. $273.70 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913775
Principal investigator 1 Aveo Pharmaceuticals, Inc. $13.89 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913777
Principal investigator 1 Aveo Pharmaceuticals, Inc. $188.02 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913779
Principal investigator 1 Aveo Pharmaceuticals, Inc. $13.89 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913781
Principal investigator 1 Aveo Pharmaceuticals, Inc. $273.70 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913783
Principal investigator 1 Aveo Pharmaceuticals, Inc. $299.32 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913785
Principal investigator 1 Aveo Pharmaceuticals, Inc. $13.89 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913787
Principal investigator 1 Aveo Pharmaceuticals, Inc. $273.70 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913789
Principal investigator 1 Aveo Pharmaceuticals, Inc. $304.92 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913791
Principal investigator 1 Aveo Pharmaceuticals, Inc. $13.89 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913793
Principal investigator 1 Aveo Pharmaceuticals, Inc. $430.92 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913795
Principal investigator 1 Janssen Research & Development, LLC $4,783.00 10/09/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer No dispute reported 06/30/2026 1175354521
Principal investigator 1 Exelixis Inc. $2,890.00 09/10/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377566
Principal investigator 1 Exelixis Inc. $2,999.00 09/10/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377570
Principal investigator 1 Exelixis Inc. $4,225.00 09/10/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377576
Principal investigator 1 Exelixis Inc. $3,056.00 09/10/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377578
Principal investigator 1 Exelixis Inc. $2,477.00 09/10/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377580
Principal investigator 1 Exelixis Inc. $4,138.00 09/10/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377582
Principal investigator 1 Exelixis Inc. $3,116.00 09/10/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377586
Principal investigator 1 Janssen Research & Development, LLC $20,519.00 09/08/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer No dispute reported 06/30/2026 1175354415
Principal investigator 1 Exelixis Inc. $2,853.90 09/01/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377588
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,000.00 08/14/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913623
Principal investigator 1 Janssen Research & Development, LLC $54,250.00 08/04/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer No dispute reported 06/30/2026 1175354324
Principal investigator 1 Exelixis Inc. $2,314.00 08/01/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377568
Principal investigator 1 Exelixis Inc. $2,836.00 08/01/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377572
Principal investigator 1 Aveo Pharmaceuticals, Inc. $124.98 07/28/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913625
Principal investigator 1 Janssen Research & Development, LLC $11,690.00 07/21/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer No dispute reported 06/30/2026 1175354406
Principal investigator 1 Exelixis Inc. $28,268.70 07/17/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377554
Principal investigator 1 Exelixis Inc. $5,082.00 07/10/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377552
Principal investigator 1 Exelixis Inc. $3,000.00 07/10/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377556
Principal investigator 1 Exelixis Inc. $10,260.80 07/10/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377558
Principal investigator 1 Exelixis Inc. $2,447.00 07/09/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377574
Principal investigator 1 Exelixis Inc. $2,314.00 07/09/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377584
Principal investigator 1 Janssen Research & Development, LLC $5,780.00 06/23/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer No dispute reported 06/30/2026 1175354239
Principal investigator 1 Exelixis Inc. $2,314.00 06/11/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377534
Principal investigator 1 Exelixis Inc. $4,841.00 06/11/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377536
Principal investigator 1 Exelixis Inc. $49,958.60 06/11/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377538
Principal investigator 1 Janssen Research & Development, LLC $23,611.00 06/06/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer No dispute reported 06/30/2026 1175354288
Recipient PFIZER INC. $940.00 05/31/2025 Covered Recipient Physician ENFORTUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228769019
Principal investigator 1 Exelixis Inc. $10,310.60 05/13/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377488
Principal investigator 1 Janssen Research & Development, LLC $6,323.00 05/08/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer No dispute reported 06/30/2026 1175354187
Principal investigator 1 Aveo Pharmaceuticals, Inc. $124.98 04/28/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913657
Principal investigator 1 Exelixis Inc. $9,234.00 04/11/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377490
Principal investigator 1 Janssen Research & Development, LLC $3,855.00 03/31/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer No dispute reported 06/30/2026 1175354454
Principal investigator 1 Aveo Pharmaceuticals, Inc. $500.00 03/25/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913639
Principal investigator 1 Aveo Pharmaceuticals, Inc. $750.00 03/25/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913641
Principal investigator 1 Aveo Pharmaceuticals, Inc. $500.00 03/25/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913643
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,250.00 03/25/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913645
Principal investigator 1 Aveo Pharmaceuticals, Inc. $500.00 03/25/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913647
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,000.00 03/25/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913649
Principal investigator 1 Exelixis Inc. $29,012.10 03/19/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377482
Principal investigator 1 Janssen Research & Development, LLC $14,690.00 03/07/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer No dispute reported 06/30/2026 1175354476
Principal investigator 1 Exelixis Inc. $94,644.40 03/03/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377484
Principal investigator 1 Exelixis Inc. $119.00 02/21/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377472
Principal investigator 1 Exelixis Inc. $560.00 02/21/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377474
Principal investigator 1 Exelixis Inc. $1,050.00 02/21/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377478
Principal investigator 1 Exelixis Inc. $3,515.00 02/10/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377466
Principal investigator 1 Exelixis Inc. $3,132.00 02/10/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377468
Principal investigator 1 Exelixis Inc. $2,999.00 02/10/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377476
Principal investigator 1 Janssen Research & Development, LLC $41,246.00 02/03/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer No dispute reported 06/30/2026 1175354181
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician ENFORTUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228770513
Principal investigator 1 Aveo Pharmaceuticals, Inc. $124.98 01/27/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913637
Principal investigator 1 Aveo Pharmaceuticals, Inc. $124.98 01/27/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913659
Principal investigator 1 Exelixis Inc. $37,837.00 01/17/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377486
Principal investigator 1 Exelixis Inc. $3,648.00 01/15/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma No dispute reported 06/30/2026 1222377480